Merck Keytruda Franchise Gets Boost from Japanese Approval

Merck's Keytruda franchise has received another boost in Japan after the country's health ministry approved the subcutaneous version of the cancer immunotherapy for all indications already cleared for intravenous Keytruda. This approval gives Japanese oncologists a faster and more convenient way to deliver the drug, taking only minutes instead of an hour-long infusion.

The decision follows the earlier clearance of the subcutaneous formulation by American regulators across most solid tumor indications. The strategic move aims to protect the franchise ahead of the eventual loss of exclusivity on the original intravenous product.

Merck is also benefiting from a positive European committee opinion for Keytruda paired with Padcev in resectable muscle-invasive bladder cancer, demonstrating the company's continued momentum in oncology. The combination regimen has shown meaningful improvements in outcomes for patients compared to standard chemotherapy-based approaches.